Education & training
National Vaccine Storage and Handling Guidelines for Immunization Providers - 2015
The objective of the National Vaccine Storage and Handling Guidelines for Immunization Providers - 2015 is to provide recommendations for vaccine storage and handling for immunization providers. Specific recommendations for vaccine storage and handling procedures may vary among public health offices and immunization programs, therefore the document is meant to supplement existing policies rather than replace them.
Pour améliorer l'immunisation des adultes : Information à l'intention du personnel soignant
La sous-immunisation contre les maladies évitables par la vaccination est courante chez les adultes canadiens. Les vaccins sont recommandés à tous les stades de la vie, mais c'est au personnel soignant qu'il incombe d'indiquer aux patients ceux dont ils ont besoin pour rester en santé et prévenir les infections. Cette présentation est offerte par Immunisation Canada pour aider les fournisseurs de soins de santé a améliorer leurs connaissances sur l'immunisation des adultes. Les renseignements contenus dans cette présentation sont fondés sur les recommandations du Comité consultatif national de l'immunisation (CCNI) et du Guide canadien d'immunisation (GCI).
Re-Immunization with Polysaccharide 23-Valent Pneumococcal Vaccine (Pneu-P-23 )
This statement will supplement previous pneumococcal statements and provide the evidence used to determine the optimal time between initial vaccination with polysaccharide 23-valent pneumococcal vaccine (Pneu-P-23) and subsequent booster doses to protect against invasive pneumococcal disease in those at highest risk for IPD.
Reducing pain during vaccine injections: clinical practice guideline
Pain from vaccine injections is common, and concerns about pain contribute to vaccine hesitancy across the lifespan. Non-compliance with vaccination compromises the individual and community benefits of immunization by contributing to outbreaks of vaccine-preventable diseases. Individuals may also engage in broader noncompliant behaviours if they acquire a fear of needles as a result of negative vaccination experiences. There are many evidence-based treatments to mitigate pain at the time of vaccination; however, most are not routinely used. The current guideline expands on and updates the 2010 guideline with recommendations across the lifespan. This enhanced scope led to a revised team name of HELPinKids&Adults. The intended audience is all health care providers who administer vaccine injections.
Revaccination avec le vaccin polysaccharidique 23-valent contre le pneumocoque (Pneu-P-23)
La présente déclaration complétera les déclarations précédentes sur le pneumocoque et fournira les données probantes utilisées pour déterminer la période optimale entre l’administration initiale du vaccin polysaccharidique 23-valent contre le pneumocoque (Pneu-P-23) et les doses de rappel ultérieures afin de protéger les personnes à risque de pneumococcie invasive (PI).
Update on Quadrivalent Meningococcal Vaccines available in Canada
The purpose of this Statement is to supplement previous conjugate meningococcal vaccine statements which have outlined the use of monovalent meningococcal C and quadrivalent conjugate meningococcal vaccines. This statement will review existing NACI recommendations on the use of conjugate meningococcal vaccines; update the epidemiology of meningococcal disease in Canada; and review and update information on quadrivalent conjugate meningococcal vaccines and vaccination schedules used in Canada.
Your child's best shot : a parent's guide to vaccination
Includes ordering information for a book that answers questions parents and caregivers may have about vaccination.
Advice for the Use of the Multicomponent Meningococcal Serogroup B (4CMenB) Vaccine
This statement updates the epidemiology of IMD in Canada; provides available vaccine efficacy, effectiveness, immunogenicity and safety information on 4CMenB vaccine; identifies evidence gaps and ongoing research, evaluation and surveillance needs; and provides recommendations for use of the 4CMenB vaccine in Canada.
Approved but non-funded vaccines: Accessing individual protection
Funded immunization programs are best able to achieve high participation rates, optimal protection of the target population, and indirect protection of others. However, in many countries public funding of approved vaccines can be substantially delayed, limited to a portion of the at-risk population or denied altogether. In these situations, unfunded vaccines are often inaccessible to individuals at risk, allowing potentially avoidable morbidity and mortality to continue to occur. The authors contend that private access to approved but unfunded vaccines should be reconsidered and encouraged, with recognition that individuals have a prerogative to take advantage of a vaccine of potential benefit to them whether it is publicly funded or not. Moreover, numbers of “approved but unfunded” vaccines are likely to grow because governments will not be able to fund all future vaccines of potential benefit to some citizens. New strategies are needed to better use unfunded vaccines even though the net benefits will fall short of those of funded programs.
Conseils relatifs à l'utilisation du vaccin multicomposant contre le méningocoque du sérogroupe B (4CM en B)
Cet énoncé met à jour l’épidémiologie de la MI au Canada; fournit les données disponibles sur l’efficacité théorique et pratique, l’immunogénicité et l'innocuité du vaccin 4CMenB; cerne les lacunes en matière de données probantes et de recherche en cours, les besoins en matière d’évaluation et de surveillance; et émet des recommandations relatives à l’utilisation du vaccin 4CMenB au Canada.